open access

Vol 86, No 5 (2018)
LETTERS
Published online: 2018-10-30
Submitted: 2018-10-14
Accepted: 2018-10-15
Get Citation

Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Response to the letter of Siniorakis et al.

Maciej Liczek, Iga Panek, Piotr Damiański, Olga Jęczeń, Jędrzej Jaźwiec, Piotr Kuna, Michał Panek
DOI: 10.5603/ARM.2018.0042
·
Pubmed: 30378656
·
Adv Respir Med 2018;86(5):257-259.

open access

Vol 86, No 5 (2018)
LETTERS
Published online: 2018-10-30
Submitted: 2018-10-14
Accepted: 2018-10-15

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Response to the letter of Siniorakis et al.

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 5 (2018)

Pages

257-259

Published online

2018-10-30

DOI

10.5603/ARM.2018.0042

Pubmed

30378656

Bibliographic record

Adv Respir Med 2018;86(5):257-259.

Authors

Maciej Liczek
Iga Panek
Piotr Damiański
Olga Jęczeń
Jędrzej Jaźwiec
Piotr Kuna
Michał Panek

References (18)
  1. Flessas N, Alexanian I, Parissis J, et al. Plasma activity of B-type natriuretic peptide in patients with biventricular heart failure versus those with right heart failure due to chronic obstructive pulmonary disease. J Cardiovasc Med (Hagerstown). 2014; 15(6): 476–480.
  2. Ambrosy AP, Mentz RJ, Fiuzat M, et al. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail. 2018; 20(6): 963–972.
  3. Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol. 2017; 14(3): 171–186.
  4. Dobrivojević M, Sinđić A, Edemir B, et al. Interaction between bradykinin and natriuretic peptides via RGS protein activation in HEK-293 cells. Am J Physiol Cell Physiol. 2012; 303(12): C1260–C1268.
  5. Golias Ch, Charalabopoulos A, Stagikas D, et al. The kinin system--bradykinin: biological effects and clinical implications. Multiple role of the kinin system--bradykinin. Hippokratia. 2007; 11(3): 124–128.
  6. Liczek M, Panek I, Damiański P, et al. Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Adv Respir Med. 2018 [Epub ahead of print].
  7. de Gouw H, Diamant E, Kuijpers E. Role of neutral endopeptidase in exercise-induced bronchoconstriction in asthmatic subjects. J Appl Physiol (1985) 1996; 81(2):673-8. Shi V, Senni M, Streefkerk H, et al. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. Int J Cardiol. 2018; 264: 118–123.
  8. D'Elia E, Iacovoni A, Vaduganathan M, et al. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail. 2017; 19(6): 710–717.
  9. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. 2001; 92(1): 1–20.
  10. Minamino N, Nishikimi T. Natriuretic Peptides. Handbook of Biologically Active Peptides. 2013: 1415–1422.
  11. Kohno M, Yokokawa K, Horio T, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 1992; 70(2): 241–247.
  12. Klinger JR, Petit RD, Warburton RR, et al. Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats. J Appl Physiol (1985). 1993; 75(4): 1615–1623.
  13. Thompson JS, Sheedy W, Morice AH. Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia. British Journal of Pharmacology. 2012; 113(4): 1121–1126.
  14. Karoor V, Oka M, Walchak SJ, et al. Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism. Hypertension. 2013; 61(4): 921–930.
  15. Maarouf CL, Walker JE, Sue LI, et al. Impaired hepatic amyloid-beta degradation in Alzheimer's disease. PLoS One. 2018; 13(9): e0203659.
  16. Saido T, Leissring MA. Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med. 2012; 2(6): a006379.
  17. Patel N, Gluck J. Is Entresto good for the brain? World J Cardiol. 2017; 9(7): 594–599.
  18. Cermakova P, Eriksdotter M, Lund LH, et al. Heart failure and Alzheimer's disease. J Intern Med. 2015; 277(4): 406–425.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl